Corcept Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About CORT
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B.
CEOJoseph K. Belanoff
CEOJoseph K. Belanoff
Employees500
Employees500
HeadquartersRedwood City, California
HeadquartersRedwood City, California
Founded1998
Founded1998
Employees500
Employees500
CORT Key Statistics
Market cap7.32B
Market cap7.32B
Price-Earnings ratio60.74
Price-Earnings ratio60.74
Dividend yield—
Dividend yield—
Average volume1.77M
Average volume1.77M
High today$71.53
High today$71.53
Low today$67.97
Low today$67.97
Open price$69.46
Open price$69.46
Volume1.28M
Volume1.28M
52 Week high$117.33
52 Week high$117.33
52 Week low$28.04
52 Week low$28.04
CORT News
Seeking Alpha 7h
Corcept's mid-stage ALS study fails to meet main goalCorcept Therapeutics (NASDAQ:CORT) said on Thursday that the mid-stage study of its cortisol modulator, dazucorilant, in patients with amyotrophic lateral scler...
Simply Wall St 3d
Corcept Therapeutics (NasdaqCM:CORT) Announces Positive Phase 3 Results For Ovarian Cancer Treatmentrecently shared promising results from its Phase 3 ROSELLA trial, demonstrating a 30% reduction in disease progression risk for relacorilant in combination with...
People also own
Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.